| CELCUITY INC. DL -,001 |
| USA |
| Gesundheit |
| US15102K1007 / A2JAAX |
| 7VR (Frankfurt) / CELC (NASDAQ) |
| FRA:7VR, ETR:7VR, 7VR:GR, NASDAQ:CELC |
| - |
| https://www.celcuity.com/ |
|
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company’s lead product candidate, gedatolisib, is designed to inhibit the PI3K/AKT/mTOR signaling pathway, wh..
>Volltext.. |
| 3705.56 Mio. EUR |
| 3650.6 Mio. EUR |
| - |
| -160.51 Mio. EUR |
| -166.1 Mio. EUR |
| -3.36 EUR |
| 278.52 Mio. EUR |
| 125.03 Mio. EUR |
| -148.54 Mio. EUR |
| 11.65 |
| - |
| -42.03% |
| - |
| - |
| - |
| - |
| CELCUITY |
| 17.06.26 |
|